Treace Medical Reports 2025 Financial Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Source: Newsfilter
- Revenue Growth: Treace Medical reported fourth-quarter revenue of $62.5 million and full-year revenue of $212.7 million, marking a 2% increase year-over-year; however, fourth-quarter revenue decreased by 9% compared to 2024, primarily due to a shift towards lower-priced product sales impacting overall revenue performance.
- Net Loss Situation: The company recorded a net loss of $9.4 million in the fourth quarter and $59.0 million for the full year 2025, an increase from 2024, although adjusted EBITDA loss was reduced by 64%, indicating efforts in cost control and operational efficiency.
- Cash Usage Reduction: Cash usage decreased by 46% to $27.3 million in 2025, reflecting improved financial management, with expectations of a further 50% reduction in cash usage for 2026, providing better funding for future growth initiatives.
- Market Expansion: By the end of 2025, the number of active surgeons increased by 202 to a total of 3,337, representing 33% of U.S. surgeons performing bunion surgeries, indicating significant progress in market penetration and customer base expansion.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TMCI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TMCI
Wall Street analysts forecast TMCI stock price to rise
6 Analyst Rating
1 Buy
4 Hold
1 Sell
Hold
Current: 4.410
Low
3.00
Averages
4.87
High
7.50
Current: 4.410
Low
3.00
Averages
4.87
High
7.50
About TMCI
Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boundless Bio Merges with Serapha in All-Stock Deal
- Merger Overview: Boundless Bio has agreed to merge with privately held Serapha Bio in an all-stock transaction expected to close in Q4 2026, with the combined entity to operate under the name Serapha Bio, Inc. and trade on Nasdaq as "AATD", enhancing its competitive position in the biopharmaceutical market.
- Cash Dividend Plan: Prior to the merger's completion, Boundless Bio plans to declare a cash dividend to existing shareholders, aimed at boosting shareholder confidence and laying a solid foundation for the upcoming merger, which is expected to attract more investor interest.
- Clinical Candidate Development: Serapha's lead clinical candidate, SERP-01, is being developed for severe Alpha-1 Antitrypsin Deficiency, which is anticipated to provide new revenue streams for the company and strengthen its market position in the therapeutic area.
- Stock Performance: Boundless Bio's stock surged 85.71% to close at $2.60, reflecting a positive market reaction to the merger news and indicating investor optimism regarding future growth potential.
See More
Treace Launches HyperPlate™ XM Implant for Midfoot Surgery
- Technological Innovation: Treace successfully completed the first surgery using the HyperPlate™ XM Dynamic Compression Locking Implant, which incorporates FastPitch® locking screws to enhance insertion speed and dynamic compression, thereby improving stability and strength in midfoot and hindfoot surgeries.
- Market Expansion: The launch of the HyperPlate™ XM implant signifies Treace's ongoing expansion in the foot and ankle market, expected to drive increased procedural utilization and deepen customer engagement and market share.
- Clinical Feedback: Dr. Paul Dayton from the Foot & Ankle Center noted that the HyperPlate™ XM implant performed exceptionally well in large joint fusion surgeries, significantly improving insertion efficiency and joint preparation, indicating a potential increase in surgical success rates.
- Commercialization Plan: Treace anticipates full commercialization of the HyperPlate™ XM implant and its suite of sterile instruments in the third quarter of 2026, further solidifying its leadership position in the foot medical technology sector.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Treace Medical (TMCI) Q4 2025 Earnings Transcript
See More
Treace Medical (TMCI) Q1 2026 Earnings Transcript
See More
Treace Medical Concepts Q1 2026 Earnings Call Insights
- Revenue Decline: Treace Medical reported Q1 2026 revenue of $47.2 million, reflecting a 10% year-over-year decline, with expectations that this trend will improve as new products launched in 2025 begin to annualize, impacting overall revenue performance.
- Full-Year Revenue Guidance: The company reaffirmed its full-year 2026 revenue guidance in the range of $202 million to $212 million, anticipating continued revenue declines until the fourth quarter, but expects growth to return driven by increased case volumes and new product launches.
- New Product Commercialization: Full commercialization of SuperBite and SpeedXM is expected in Q3 2026, collectively expanding the total addressable market by approximately $300 million, thereby enhancing the company's competitive position in the foot and ankle market.
- Adjusted EBITDA Loss: The company anticipates an adjusted EBITDA loss ranging from $4 million to $6 million for 2026, while also expecting a 50% reduction in cash usage compared to 2025, indicating a focus on cost control.
See More
Boundless Bio Merges with Serapha in All-Stock Deal
- Merger Overview: Boundless Bio has agreed to merge with privately held Serapha Bio in an all-stock transaction expected to close in Q4 2026, with the combined entity to operate under the name Serapha Bio, Inc. and trade on Nasdaq as "AATD", enhancing its competitive position in the biopharmaceutical market.
- Cash Dividend Plan: Prior to the merger's completion, Boundless Bio plans to declare a cash dividend to existing shareholders, aimed at boosting shareholder confidence and laying a solid foundation for the upcoming merger, which is expected to attract more investor interest.
- Clinical Candidate Development: Serapha's lead clinical candidate, SERP-01, is being developed for severe Alpha-1 Antitrypsin Deficiency, which is anticipated to provide new revenue streams for the company and strengthen its market position in the therapeutic area.
- Stock Performance: Boundless Bio's stock surged 85.71% to close at $2.60, reflecting a positive market reaction to the merger news and indicating investor optimism regarding future growth potential.
See More
Treace Launches HyperPlate™ XM Implant for Midfoot Surgery
- Technological Innovation: Treace successfully completed the first surgery using the HyperPlate™ XM Dynamic Compression Locking Implant, which incorporates FastPitch® locking screws to enhance insertion speed and dynamic compression, thereby improving stability and strength in midfoot and hindfoot surgeries.
- Market Expansion: The launch of the HyperPlate™ XM implant signifies Treace's ongoing expansion in the foot and ankle market, expected to drive increased procedural utilization and deepen customer engagement and market share.
- Clinical Feedback: Dr. Paul Dayton from the Foot & Ankle Center noted that the HyperPlate™ XM implant performed exceptionally well in large joint fusion surgeries, significantly improving insertion efficiency and joint preparation, indicating a potential increase in surgical success rates.
- Commercialization Plan: Treace anticipates full commercialization of the HyperPlate™ XM implant and its suite of sterile instruments in the third quarter of 2026, further solidifying its leadership position in the foot medical technology sector.
See More
Biotech Companies See Significant Stock Gains
- Parabilis Debut Performance: Parabilis Medicines Inc. saw its stock surge 58% on its Nasdaq debut, pricing 33.5 million shares at $20 each, with expected gross proceeds of approximately $670 million, indicating strong market demand for its innovative drug candidates.
- Clover Health Legal Victory: Clover Health Investments Corp. achieved a legal victory against the U.S. Department of Health and Human Services, upgrading its PPO plan's star rating from 3.5 to 4.5, with projected total revenues for 2026 between $2.81 billion and $2.92 billion, reflecting a 49% year-over-year growth.
- Shoulder Innovations Growth: Shoulder Innovations, Inc. reported a net revenue of $16.7 million for Q1, a 65% increase year-over-year, and expects full-year 2026 revenues between $65 million and $68 million, representing a growth of 37% to 44%, showcasing its strong position in the shoulder surgical market.
- Myomo Stock Surge: Myomo Inc.'s stock rose over 17%, with projected Q2 2026 revenues between $10.3 million and $10.8 million, compared to $9.7 million in Q2 2025, reflecting increasing market demand for its wearable medical robotics products.
See More
Treace Medical (TMCI) Q4 2025 Earnings Transcript
See More
Treace Medical (TMCI) Q1 2026 Earnings Transcript
See More
Treace Medical Concepts Q1 2026 Earnings Call Insights
- Revenue Decline: Treace Medical reported Q1 2026 revenue of $47.2 million, reflecting a 10% year-over-year decline, with expectations that this trend will improve as new products launched in 2025 begin to annualize, impacting overall revenue performance.
- Full-Year Revenue Guidance: The company reaffirmed its full-year 2026 revenue guidance in the range of $202 million to $212 million, anticipating continued revenue declines until the fourth quarter, but expects growth to return driven by increased case volumes and new product launches.
- New Product Commercialization: Full commercialization of SuperBite and SpeedXM is expected in Q3 2026, collectively expanding the total addressable market by approximately $300 million, thereby enhancing the company's competitive position in the foot and ankle market.
- Adjusted EBITDA Loss: The company anticipates an adjusted EBITDA loss ranging from $4 million to $6 million for 2026, while also expecting a 50% reduction in cash usage compared to 2025, indicating a focus on cost control.
See More
